Cite
MLA Citation
Jonathan W Goldman et al.. “Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.” Lancet oncology, vol. 22, no. 1, 2021, pp. 51–65. http://access.bl.uk/ark:/81055/vdc_100119331369.0x000014